跳至主要内容
临床试验/2024-511916-25-00
2024-511916-25-00
招募中
1/2 期

Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors

Pharma Mar S.A.7 个研究点 分布在 2 个国家目标入组 115 人2024年4月26日
干预措施PM14
相关药物PM14

概览

阶段
1/2 期
干预措施
PM14
疾病 / 适应症
未指定
发起方
Pharma Mar S.A.
入组人数
115
试验地点
7
主要终点
Patients with dose limiting toxicities
状态
招募中
最后更新
去年

概览

简要总结

Despite recent advances in the treatment of solid tumors in general, advanced (metastatic) disease remains mostly incurable and there is an urgent need to develop new therapeutic options for these patients, particularly investigational drugs with novel mechanisms of action. The investigation of new combination regimens of non-crossresistant agents with acceptable-and not completely overlapping-toxicities has been a major way to improve response rate and outcome of patients with advanced solid tumors.

详细描述

First-in-human, open-label, dose-finding, phase I trial, using a classical 3+3 design followed by a continual reassessment method (CRM). Patients will be included in cohorts of a minimum of three or six patients to receive PM14 at successively increasing dose levels, starting at 0.25 mg/m\^2 for the Days 1 and 8 schedule. For the Day 1 schedule, the starting dose will be 4.5 mg/m\^2. Dose escalation will proceed only after all the patients fully evaluable for DLT included at one dose level have completed the first cycle (i.e., three weeks). Once the RD has been determined, expansion cohorts will be included to have a minimum of 20 fully evaluable patients per indication (tumor type) treated in the Expansion phase (regardless of the schedule administered), and thus have an adequate number of patients to assess safety. The indications of these patients will be chosen depending on the efficacy data obtained during dose escalation. Patients treated at the expansion cohorts will be evaluable by the Response Evaluation Criteria in Solid Tumors (RECIST v.1.1) and/or by serum markers only in patients with prostate cancer (prostate specific-antigen \[PSA\]) or ovarian cancer (carbohydrate antigen-125 \[CA-125\]) according to the Prostate-Specific Antigen Working Group Recommendations (PSAWGR) and the Gynecologic Cancer Intergroup (GCIG) specific criteria, respectively.

注册库
euclinicaltrials.eu
开始日期
2024年4月26日
结束日期
待定
最后更新
去年
研究类型
Interventional
研究设计
Single Group

研究者

责任方
Principal Investigator
主要研究者

Clinical Development Oncology Unit

Scientific

Pharma Mar S.A.

入排标准

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

PM14

Patients will receive PM14 as an i.v. infusion in a total volume of 100 mL of 0.9% sodium chloride at the first three dose escalation levels. Thereafter, the volume of infusion can be increased to 250 mL.

干预措施: PM14

结局指标

主要结局

Patients with dose limiting toxicities

时间窗: At cycle 2 (21-days cycle)

To identify the dose limiting toxicities (DLTs), and to determine the maximun tolerated dose (MTD) and the recommended dose (RD) of PM14 administered i.v. on two days (Day 1 and Day 8) or on Day 1 only, both every three weeks (q3wk) over three hours to patients with advanced solid tumors.

Overall response rate

时间窗: Through study completion up to Cycle 9

To confirm the recommended dose (RD) determined during the Dose escalation phase, and to evaluate the antitumor activity of PM14 in terms of overall response rate (ORR), according to the Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1, and/or serum markers as appropriate, in patients with selected advanced solid tumors.

次要结局

  • Clinical Benefit Rate(Through study completion up to Cycle 9)
  • Pharmacokinetic: Maximum Plasma Concentration (Cmax)(At the end of Cycle 1 (each cycle is 21 days))
  • Pharmacogenomic: Number of patients with RNA/protein expression(At the end of Cycle 1 (each cycle is 21 days))
  • Progression-free Survival(From the date of first infusion of study treatment to the date of first documented progression or date of death from any cause, assessed up to 72 months)
  • Duration of Response(From the date of the first documentation of response to the date of first PD or further therapy or death, assessed up to 72 months)
  • Incidence of Treatment-Emergent Adverse Events(From the date of first infusion of study treatment to the date of study termination, assessed up to 72 months)
  • Pharmacogenetic(At the end of Cycle 1 (each cycle is 21 days))
  • Pharmacogenomic: Number of patients with Polymorphisms(At the end of Cycle 1 (each cycle is 21 days))
  • Pharmacokinetic: Area Under The Concentration-time Curve (AUC)(At the end of Cycle 1 (each cycle is 21 days))
  • Pharmacogenomic: Number of patients with Mutations(At the end of Cycle 1 (each cycle is 21 days))

研究点 (7)

Loading locations...

相似试验